At the IGTP TODAY

News

- Research

Induced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer

The study, by the Hereditary Cancer research group at the IGTP, focuses on characterizing induced pluripotent stem cells (iPSCs) from benign tumors, characteristic of Neurofibromatosis type 1 (NF1). The iPSCs are able to regenerate indefinitely and give rise to any other cell in the body so they represent an inexhaustible supply of cells to study tumors and new treatments.

- Campus Can Ruti, Research

Phakomatosis experts get together at the IGTP

The professionals that make up the Reference Centre (CSUR) on Neurocutaneous Syndromes- Phakomatoses, have met up together at the IGTP. The aim of these regular meetings and mini-symposiums is to revise the work done in healthcare and research, including innovations, new approaches and the lines of research underway. The prescence of different professionals in the meeting provides a more global view of the work carried out by the whole group and a better reciprocal understanding of the healthcare and research aspects.

- Research

The Hereditary Cancer Group at the IGTP provides another tool for the better management of patients diagnosed with NF1

In a study, published in Human Mutation led by Meritxell Carrió and Eduard Serra of the IGTP in collaboration with scientists from the ICO Hereditary Cancer Program, scientists studied 8 PNF tumours to find information to help doctors predict how tumours will develop.  They looked at the tissue characteristics of the tumors and then compared this to the genetic make-up of the cells within the tumour.